Trials / Completed
CompletedNCT00657579
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension
A Randomized, Double-Masked, Parallel-Group, Dose-Response Trial of DE-104 Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Santen Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the dose-response relationship of DE-104 ophthalmic solution in lowering intraocular pressure (IOP) in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DE-104 ophthalmic solution, low concentration | |
| DRUG | DE-104 ophthalmic solution, medium concentration | |
| DRUG | DE-104 ophthalmic solution, high concentration | |
| DRUG | DE-104 vehicle |
Timeline
- First posted
- 2008-04-14
- Last updated
- 2009-03-16
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00657579. Inclusion in this directory is not an endorsement.